

RESEARCH ARTICLE

- In Vitro* Antidiabetic and *In Vivo* Antidiarrheal Activity of *Oncoba Spinosa* Roots 121 – 128
Prasanth Kumar M, Suba V., Ramireddy B and Srinivas Babu P
- Antihyperglycemic, Antioxidant, and Pancreas Protective Effects of *Coriandrum Sativum* Seed in Alloxan-Induced Diabetic Rats 129 – 133
Gunawan Pamudji Widodo, Sri Rejeki Handayani and Rina Herowati
- Purification and Characterization of Polysaccharide from Microalgae BTM11 as Inhibitor of Hepatitis C Virus RNA Helicase 134 – 140
Apon Zaenal Mustopa, Aksar Chair Lages, Muhammad Ridwan1, Linda Sukmarini, Dwi Susilaningsih, Hasim and, Delicia
- Overproduction of Mercuric Reductase From Mercury-Resistant Bacteria 141 – 146
Klebsiella pneumoniae Isolate A1.1.1
Fatimawali, Billy Kepel and Trina Ekawati Tallei
- Naringenin-Loaded Chitosan Nanoparticles Formulation, and its *In Vitro* Evaluation Against T47D Breast Cancer Cell Line 147 – 157
Lina Winarti, Lusia Oktora Ruma Kumala Sari and Agung Endro Nugrobo
- Mutation Induction for Improving of Artemisinin Content in Each Part of *Artemisia Cina* Mutan Lines 158 – 165
Aryanti and Marina Yuniawati
- Effect of Dialyzer Reuse Upon Urea Reduction Ratio (URR), KT/V Urea and Serum Albumin Regular Hemodialysis Patient 166 – 170
Ni Made Amelia R. Dewi, Budi Suprpti and I Gde Raka Widiana
- Determination of Elemental Impurities in Some Commercial Paediatric and Adult Formulations of Artemether – Lumefantrine in the Nigerian Market by Atomic Absorption Spectroscopy 171 – 176
Sunday O. Awofisayo, Augustine O. Okhamafe and Mathew I. Arbewoh



Publishing Office

Faculty of Pharmacy, Universitas Gadjah Mada
Sekip Utara Yogyakarta Indonesia 55281
Telp.: (0274)543120 Fax. : (0274)543120
Email : farmasi@ugm.ac.id



Indonesian. J. Pharm.
Volume 26 Issue 3 (2015)
July - September



Indonesian Journal of Pharmacy

Volume 26 Issue 3 (2015)

ISSN : 2338-9427
Formerly ISSN : 0126-1037

Indonesian Journal of Pharmacy (Indonesian J. Pharm.)

Accredited by DGHE (DIKTI) No. 58/DIKTI/Kep/2013



STT NO. 1652/SK/DITJEN PPG/SST/1990

Faculty of Pharmacy
Universitas Gadjah Mada



**INDONESIAN JOURNAL OF PHARMACY
(INDONESIAN J. PHARM)**

ISSN : 2338-9427
STT. No. 1652/SK/DITJEN PPG/STT/1990
(Formerly SIT No. 1404/1972)



Indonesian J. Pharm., (Formerly Majalah Farmasi Indonesia) established in 1972, is a quarterly journal, open access, peer-reviewed, and online international pharmacy journal. Indonesian J. Pharm is indexed in Google Scholar, Index Copernicus, GetCITED, Genamics Journal Seek New Jersey USA, Geneva Foundation for Medical Education and Research (GFMER), Pharmaceutical Sciences Open Access Resources (PSOAR), International Pharmaceutical Abstracts (IPA), Inherent Digital Library UGM, WorldCat, Socolar, SCIRUS Elsevier, Indonesian Scientific Journal Database (ISJD), DOAJ, CABI, Pro-Quest, EBSCO Publishing Database, Crossref and being processed to be indexed in Academic Journal Database, ISI Thompson, SCOPUS, Open J Gate PUBMED and Biological abstract.

DIRECTOR

Prof. Dr. Subagus Wahyuono.

Faculty of Pharmacy, Universitas Gadjah Mada, Sekip Utara, Yogyakarta Indonesia, 55281.

EDITOR-IN-CHIEF

Dr. Agustinus Yuswanto

Faculty of Pharmacy, Universitas Gadjah Mada, Sekip Utara, Yogyakarta Indonesia, 55281. Email : ag_yuswanto@ugm.ac.id

ASSOCIATE EDITOR

Prof. Dr. Agung Endro Nugroho, Faculty of Pharmacy, Universitas Gadjah Mada Indonesia

Dr. Abdul Rohman, Faculty of Pharmacy, Universitas Gadjah Mada Indonesia

Dr. Montarat Tavorncharoenshap, Dept of Pharmacy, Mahidol University, Thailand

Dr. Jun An, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, PR China

Dr. Karuna Shanker, CSIR-Central Institute of Medical and Aromatic Plants, India

Prof. Dr. Sugiyanto, Faculty of Pharmacy, Universitas Gadjah Mada Indonesia

Dr. Pudjono, Faculty of Pharmacy, Universitas Gadjah Mada Indonesia

Dr. Md. Emamussalehin Choudhury, Dept Pharmacology, Bangladesh Agriculture University, Mymensingh Bangladesh

Dr. Abdul Wahab, Dept of Pharmacy, Kohat University of Science and Technology Kohat, KPK, Pakistan

Dr. Tony Hadibarata, Institute of Environment and Water Resources Management (IPASA), Universiti Teknologi Malaysia (UTM), Malaysia

ADVISORY EDITORIAL

Prof. Dr. Henk Timmerman, Vrije Universiteit Amsterdam - the Netherlands

Prof. Dr. Kazutaka Maeyama, Dept Pharmacology, School of Medicine, Ehime University, Japan

Prof. Dr. Mashasi Kawaichi, Nara Institute of Science and Technology (NAIST) Japan

Prof. Dr. Lukman Hakim, Laboratory of Pharmacology and Toxicology, Faculty of Pharmacy, Universitas Gadjah Mada Indonesia

Prof. Dr. Edy Meiyanto, Cancer Chemoprevention Research Center Indonesia

Prof. Dr. Rafeeq Alam Khan, College of Medicine-Jeddah King Saus bin Abdul Aziz University of Health Sciences, Kingdom of Saudi Arabia

Prof. Dr. Marchaban, Dept Pharmaceutics, Faculty of Pharmacy, Universitas Gadjah Mada Indonesia

Prof. Dr. Achmad Fudholi, Dept Pharmaceutics, Faculty of Pharmacy, Universitas Gadjah Mada Indonesia

Prof. Dr. Gunawan Indrayanto, Faculty of Pharmacy, Universitas Airlangga Surabaya Indonesia

Prof. Dr. Veeresh P. Veerapur, Dept of Quality Assurance, Sree Siddaganga College of Pharmacy, Karnataka, India.

Prof. Dr. Shufeng Zhou, College of Pharmacy and Morsani College of Medicine, University of Florida, USA

Dr. Joseph David Francis Tucci, Pharmacy Course Advisor, School of Pharmacy and Applied Science, La Trobe University, Bendigo, Australia

Dr. Saikat Kumar Basu, Department of Biological Sciences, University of Lethbridge, Lethbridge, Canada

Production Manager

Navista Sri Octa U, M.Sc., Apt.

Lay Out & Design

Puma Arfah, Amd.

English Editor

Dwi Larasati S, S. Farm., Apt.

Administrator

Intan Purbaningsih

Editorial Office

Indonesian Journal of Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Sekip Utara, Yogyakarta Indonesia, 55281.
Telp: 62-274-6645911, Fax: 62-274-543120, Email: mfi@ugm.ac.id or mfi.ugm@gmail.com
Homepage: <http://indonesianjpharm.farmasi.ugm.ac.id>

Publishing Office

Faculty of Pharmacy, Universitas Gadjah Mada, Sekip Utara, Yogyakarta Indonesia, 55281.
Telp: +62-274-543120; Fax: +62-274-543120 Email: farmasi@ugm.ac.id

Publication of the journal is supported by Faculty of Pharmacy, Universitas Gadjah Mada Indonesia, and affiliated with Indonesian Pharmacist Association (IAI) (Ikatan Apoteker Indonesia).



TABLE OF CONTENTS

Indonesian Journal of Pharmacy
ISSN-p : 2338-9427
Formerly ISSN-p : 0126-1037

Vol : 26, No.3 July-September 2015
<http://indonesianjpharm.farmasi.ugm.ac.id>
Published since 1972

Table of Contents

i – ii

RESEARCH ARTICLE

- In Vitro* Antidiabetic and *In Vivo* Antidiarrheal Activity of *Oncoba Spinosa* Roots** 121 – 128
Prasanth Kumar M, Suba V., Ramireddy B and Srinivas Babu P
- Antihyperglycemic, Antioxidant, and Pancreas Protective Effects of *Coriandrum Sativum* Seed in Alloxan-Induced Diabetic Rats** 129 – 133
Gunawan Pamudji Widodo, Sri Rejeki Handayani and Rina Herowati
- Purification and Characterization of Polysaccharide from Microalgae BTM11 as Inhibitor of Hepatitis C Virus RNA Helicase** 134 – 140
Apon Zaenal Mustopa, Aksar Chair Lages, Muhammad Ridwan1, Linda Sukmarini, Dwi Susilaningsih, Hasim and, Delicia
- Overproduction of Mercuric Reductase From Mercury-Resistant Bacteria *Klebsiella pneumoniae* Isolate A1.1.1** 141 – 146
Fatimawali, Billy Kepel and Trina Ekawati Tallei
- Naringenin-Loaded Chitosan Nanoparticles Formulation, and its *In Vitro* Evaluation Against T47D Breast Cancer Cell Line** 147 – 157
Lina Winarti, Lusia Oktora Ruma Kumala Sari and Agung Endro Nugroho
- Mutation Induction for Improving of Artemisinin Content in Each Part of *Artemisia Cina* Mutan Lines** 158 – 165
Aryanti and Marina Yuniawati
- Effect of Dialyzer Reuse Upon Urea Reduction Ratio (URR), KT/V Urea and Serum Albumin Regular Hemodialysis Patient** 166 – 170
Ni Made Amelia R. Devi, Budi Suprapti and I Gde Raka Widiana
- Determination of Elemental Impurities in Some Commercial Paediatric and Adult Formulations of Artemether – Lumefantrine in the Nigerian Market by Atomic Absorption Spectroscopy** 171 – 176
Sunday O. Awofisayo, Augustine O. Okhamafe and Mathew I. Arbewob



Cover:

See Gunawan Pamudji W, Page 132

Figure 1. Histopathology of the pancreas 132.

See Lina Winarni, Page 154-155

Figure 6. Apoptosis assay against T47D cells line

ACCREDITED BY DGHE (DIKTI) No. 58/DIKTI/Kep/2013

Indonesian J. Pharm., established in 1972, is a quarterly published, open access, peer-reviewed and online international pharmacy journal. Indonesian J. Pharm. is indexed in Google Scholar, Index Copernicus, GetCITED, Genamics Journal Seek New Jersey USA, Geneva Foundation for Medical Education and Research (GFMER), Pharmaceutical Sciences Open Access Resources (PSOAR), International Pharmaceutical Abstracts (IPA), Inherent Digital Library UGM, WorldCat, Virtual Library (Pharmacy Page), EBSCO Publishing Database, Socolar, SCIRUS Elsevier, Indonesian Scientific Journal Database (ISJD), DOAJ, CABI, Pro-Quest Crossref and being processed to be indexed in Academic Journal Database, ISI Thompson, PUBMED, Biological abstract. The journal is under planning to be indexed with Scopus and Open J Gate



Sertifikat

Kutipan dari Keputusan Direktur Jenderal Pendidikan Tinggi
Kementerian Pendidikan dan Kebudayaan Republik Indonesia
Nomor: 58/DIKTI/Kep/2013, Tanggal 22 Agustus 2013
Tentang Hasil Akreditasi Terbitan Berkala Ilmiah
Periode I Tahun 2013

Nama Terbitan Berkala Ilmiah
Majalah Farmasi Indonesia (Indonesian Journal of Pharmacy)
ISSN: 0126-1037
Penerbit: Fakultas Farmasi UGM

Ditetapkan sebagai Terbitan Berkala Ilmiah

TERAKREDITASI

Akreditasi sebagaimana tersebut di atas berlaku selama
5 (lima) tahun sejak ditetapkan.

Jakarta, 23 Agustus 2013

a.n. Direktur Jenderal Pendidikan Tinggi
Direktur Penelitian dan Pengabdian Kepada Masyarakat,



Prof. Agus Subekti, M.Sc., Ph.D.

NIP. 19600801 198403 1 002

NARINGENIN-LOADED CHITOSAN NANOPARTICLES FORMULATION, AND ITS *IN VITRO* EVALUATION AGAINST T47D BREAST CANCER CELL LINE

Lina Winarti¹, Lusia Oktora Ruma Kumala Sari¹, Agung Endro Nugroho^{2*}

¹Dept of Pharmaceutics,
Faculty of Pharmacy,
University of Jember,
Jember 68121, Indonesia;

²Dept of Pharmacology and
Clinical Pharmacy, Faculty
of Pharmacy, Universitas
Gadjah Mada, Yogyakarta
55281, Indonesia.

Submitted: 02-04-2015

Revised: 11-05-2015

Accepted: 22-06-2015

*Corresponding author
Agung Endro Nugroho

Email:
agungendronugroho@gmail
.com

ABSTRACT

Naringenin (NAR), a natural flavonoid aglycone of naringin has been extensively investigated for its pharmacological activities, including anti-tumor effects. However, its poor bioavailability has been identified as the single most important challenge in oral drug delivery. Based in this condition, it is used nanoencapsulation to increase the effectiveness of NAR as anti-cancer. The objectives of this research were to develop the formulation of NAR-loaded nanoparticles (NARNPs) as well as to evaluate its potential as anti-cancer against T47D breast cancer cells line. NARNPs is prepared through the method of ionic gelation, meanwhile its characteristic is evaluated through photon correlation spectroscopy (PCS), transmission electron microscopy (TEM), fourier transform infra-red spectroscopy (FTIR), and different scanning calorimeter (DSC). The result of MTT test and cellular uptake indicate that NARNPs increase cytotoxicity and internalization of NAR to the cells compared to that of free NAR. The result of qualitative apoptosis study using fluorescence microscope indicates that both free NAR and NARNPs were able to induce apoptosis. It can be conclude that Chitosan nanoparticles-TPP conjugates have the capability to encapsulate naringenin hence increase the cellular uptake and cytotoxicity of naringenin against T47D cell line. NARNPs also could induce the apoptosis effect.

Keywords: NAR, Chitosan (CS), ionic gelation, nanoparticles

INTRODUCTION

NAR (4',5,7-trihydroxyflavanone) is a compound included in flavonoid class. This compound originally comes from orange (*Citrus reticulata* and *Citrus aurantium*) (De Leo and De Bosco, 2005; Tripoli *et al.*, 2007) and is frequently distributed in citrus fruit (Dembinski *et al.*, 2004), tomatoes (Le Gall *et al.*, 2003), cherries (Wang *et al.*, 1999), grapefruit (Erlund *et al.*, 2001), and cocoa (Stark *et al.*, 2005). It has a character of not being dissolved in water because it is an aglycone. NAR is a chemopreventive agent that has been proven of being cytotoxic to the gastric cancer cells (KATOIII and MKN-7) and liver cancer cells (HepG2, Hep3B, Huh7) by inducing apoptosis through different pathway from p53 (Kanno *et al.*, 2005; Chang *et al.*, 2008). In addition, NAR is also able to induce apoptosis through induction activation of NF- κ B on HL-60 cells as well as activation of p38 MAPK and

JNK1/2 (Kanno *et al.*, 2005; Kanno *et al.*, 2006; Gopalakrishnan *et al.*, 2006)

NAR has been researched as doxorubicin co-chemotherapy (Junedi *et al.*, 2010). Doxorubicin usage in the long term has a potential to cause cardiotoxicity and insensitivity of cancer cells on doxorubicin. NAR is able to induce apoptosis through different pathway from p53 (Zhang *et al.*, 2009), therefore it is able to increase cancer cell sensitivity that has been resistant to doxorubicin as well as to cancer cell which has mutated p53 characteristic (Junedi *et al.*, 2010; Fitriyanti *et al.*, 2010).

These researchs demonstrate the potential of NAR as chemopreventive agent. However due to its poor solubility, its absorption capability into the body is so poor. An interesting technique to overcome this condition is nanoencapsulation, therefore the bioavailability of NAR can be increased

through its pharmacokinetic as well as bio-distribution.

Nanoparticle using biodegradable polymer material such as chitosan (CS) has gained attention to be developed, particularly in the development of oncological therapy. CS is composed of 2 sub-units of D-Glucosamin and N-asetil-D-glucosamin which were bound together by (1,4) glycosidic bond (LeHoux and Grondin, 1993; Rowe *et al.*, 2006). Amine group on glucosamine unit of CS is important part, because it gives high and reactive positive charge. Positive charge of CS is able to form complex along with anion compound. CS is also able to increase the transport of medicine that passes cell membrane (Winarti *et al.*, 2011; Martien and Loretz, 2007)

The formulation of CS with NAR on this research becomes nanoparticle that is expected to provide high intracellular uptake due to its unique sub-cellular size compared to the microscopic system (Mosquera *et al.*, 2001). Therefore, the potential of being anti-cancer is able to be increased compared to the use of the initial compound, which in this case is NAR.

MATERIAL AND METHODS

Low viscous CS [2-amino-2-deoxy-(1→4)-β-D glucopyranan] p.a, Pentasodium tripolyphosphate (TPP) p.a, and NAR ≥95% p.a which were obtained from Sigma, Germany. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide], DMEM, and FBS which were ordered from Sigma-Aldrich, T47D cell line which is obtained from Parasitology Laboratories, Faculty of Medicine, University of Gadjah Mada, Yogyakarta. Other chemicals were in analytical grade.

Preparation of CS nanoparticles

CS nanoparticles was prepared through ionic gelation method (Calvo *et al.*, 1997) with some modification. CS solutions (0.02%; 0.04%; 0.06%; 0.08%; 0.10% w/v) were prepared by dissolving CS in acetic acid (0.15%v/v). TPP solution (0.1%w/v) is prepared by dissolving it in double distilled water. CS nanoparticles were prepared spontaneously by adding 6mL of TPP solutions and 3.6mL of Tween-80 (0.01%v/v) as an emulsifier dropwise into 30mL of CS solution under a constant magnetic stirring at 1000rpm.

The nanoparticles were formed by ionic interaction of CS and TPP as cross-linker.

Preparation of NARNPs

To mix drug with CS nanoparticles, the pure NAR powder was dissolved into 96% of ethanol to produce 0.2%w/v NAR solution. Afterward, the NAR solution was mixed with 0.02%; 0.04%; 0.06%; 0.08%; and 0.10% w/v CS solutions under magnetic stirring. Then, 1.5mL of TPP solution (0.1%w/v) and 1.075mL of Tween-80 solution (0.01%v/v) were added dropwise into mixtures under magnetic stirring at 1000rpm, and NAR loaded CS nanoparticles were simultaneously obtained.

Physical characterization of nanoparticles

Evaluation of encapsulation efficiency (EE)

EE of NAR was determined by measuring the ultraviolet (UV) absorption of the each supernatant of NARNPs which is obtained after ultracentrifugation. The corresponding calibration curves were made by subjecting the supernatants of standards NAR solutions (5; 10; 15; 20; 25ppm) under UV/Vis spectro-photometer (Shimadzu, Japan). NAR is measured at 290nm (λ_{max}). EE of NAR is calculated according to the following formula:

$$\text{Entrapment efficiency (EE) (\%)} = \frac{W_t - W_f}{W_t} \times 100 \dots (1)$$

Meanwhile, W_t is the total initial amount of NAR and W_f is the amount of free NAR in the supernatant after ultracentrifugation (15.000rpm, 80min). All measurement were performed in triplicate and results were reported as mean \pm standard deviation.

Particle Size and Particle Size Distribution

The result of cross-linked CS nanoparticles were then analyzed for mean particles size and particle size distribution by *Delsa™ Nano Submicron Particle size*. Five mL of aquadest is added to 2 drops of NARNPs and 3mL of the mixture is taken and put into cuvette to be analysed.

Determination of zeta (ζ) Potential

Zeta potential measurement of NARNPs dispersion were performed by using a *Delsa™ Nano Submicron Particle size* at 25°C. The zeta

potential value was measured at the default parameters of dielectric constant, refractive index, and viscosity of water. The sampling time was set to automatic.

Morphology of nanoparticles

Drops of 10mL of freshly prepared nanoparticle solution were placed on pioloform coated grids and dried for 15 min. The fluid was removed while the dried nanoparticles remaining on the grids. These grids were dried and examined by transmission electron microscope (JOEL-JEM 1400, Japan) with an in-column energy filter (EFTEM). Therefore, it was analyzed 120kV of nanoparticles energy loss, which depends on their density. Thus, nanoparticles were analyzed 120kV energy loss, depending on their density. Digital micrographs were obtained from TEM digital imaging/scanning circuitry which displays TEM images.

FTIR analysis

The FTIR spectrum of the specimen is recorded with infrared spectrophotometer. FTIR spectra were taken in the wavelength region of 4000 to 400 cm^{-1} at room temperature by using potassium bromide pellets (Merck, IR grade) for CS, TPP, NAR, and NARNPs. The samples were allowed to form pellets at pressure of 10.3×10^4 Pa.

Differential Scanning Calorimetry (DSC)

The thermal behavior of the NAR and NARNPs were characterized by DSC (Mettler Toledo DSC). Approximately 3 to 6mg of the freeze dried particles were weighed into an aluminium pan. The nanoparticles were heated from 30 to 360°C at a heating rate of 10°C/min per cycle. To maintain inert atmosphere, nitrogen was purged at the flow rate of 20cc/min.

Observation of the Cellular Uptake

T47D cells were seeded in six-well plates with cover slip which was coated at the bottom of the well. The cells were incubated in CO₂ incubator until starvation. Cells media was replaced with a new media. 1000uL of NAR nanoparticle was added afterwards, then incubated. After incubation as long as 24h, methanol was added for 30s then discarded

right away. Cover slip containing the cells were attached on the object glass and then observed through a fluorescent microscope (Zeiss).

In vitro cytotoxicity assay

Cytotoxicity of NARNPs was studied against T47D cells. T47D cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Sigma) supplemented with 10% FBS. The cells culture medium was maintained at 37°C in a humidified incubator which contains 5% of CO₂. Trypsinized confluent cells monolayer (75-80%) and the cells in the exponentially growing phase were used for cytotoxicity experiments.

MTT assay for in vitro cell viability studies

The cytotoxicity assay of NARNPs against T47D cells was evaluated by using MTT assay. The cytotoxicity of the nanoparticles was determined after 24h incubation with T47D cells. The cells were plated at a density of 5×10^3 cells/well (optimal seeding density) in 96 well plates at 37°C in 5% CO₂. The purpose was to determine cells cytotoxicity/viability.

After 12h of incubation was performed, the medium in the wells was replaced with the fresh medium containing nanoparticles of 1000µM NAR concentrations. After 24h, MTT dye solution (20µL, 5mg/mL in phosphate buffer pH-7.4) was added to each well. The incubation was further continued for another 2h at 37°C and 5% of CO₂ for exponentially growing cells. The medium in each well containing unbound MTT and dead cells was removed by suctioning process. The formazan crystals were solubilized with 100µL of DMSO, and the solution was optimally mixed to dissolve the reacted dye. The absorbance of each well was readable to a microplate reader at 540nm. The control experimental medium did not contain nanoparticles. Blank CS nanoparticles were used in evaluating its effect to cells viability. The spectro-photometer was calibrated to zero absorbance by using culture medium with no cells. The relative cell viability (%) associated to control wells containing cell culture medium without nanoparticles was calculated by :

$$[A]_{\text{test}}/[A]_{\text{control}} \times 100 \dots \dots \dots (2)$$

where [A]_{test} was the absorbance of the test sample and [A]_{control} was the absorbance of control sample.

Apoptosis assay

T47D cells of 5×10^4 /mL were distributed into 24-well plate previously coated with cover slip at the bottom followed by incubation until returning to normal. Cells were treated with NARNPs and incubated for 15h. These cells were washed slowly at the end of the incubation and cover slip containing the cells was then transferred to the top of the slide and it was added 10mL of reagent AE. The cells were then observed under a fluorescent microscope as soon as possible after the reagent becomes dry.

RESULTS AND DISCUSSION

Nanoparticles formulation selection

Formulation optimization of NARNPs was conducted by mixing CS solution with a concentration of 0.02, 0.04, 0.06, 0.08, and 0.1% to NAR solution with a concentration of 0.2% in this preliminary experiment. These five formula was stored for 3 days long at room temperature (Winarti *et al.*, 2011; Martien and Loretz, 2007). The purpose was to observe the formation of sediment. Nanoparticles with CS concentration of 0.06, 0.08, 0.10% were the most stable until 3 days, therefore these three formula were chosen for further characterization.

Encapsulation Efficiency (EE) of NARNPs

EE evaluation was conducted by spectrophotometer UV-Vis measured at 290nm (λ_{max}). The EE of NARNPs increased by the way of increasing the concentration of CS as shown in Table I. The EE for NARNPs were on the range of 42.22 ± 0.696 - $64.45 \pm 0.028\%$. Meanwhile, increasing CS concentration from 0.08% to 0.10% do not increase EE because the effect of CS-TPP mass ratio. The obtained results were in accordance with previous researches of catechins delivery. It was mentioned that the encapsulation efficiency of tea catechins decreases from 45.14 to 32.23% as the CS-TPP mass ratio increases from 4:1 to 9:1 (Hu *et al.*, 2012).

Characterization of NARNPs using Particle Size Analyzer and Zeta Sizer

Dynamic light scattering measure the zeta potential and particle size distribution. The particle size of NARNPs increases through increasing the CS concentration from 0.06% to 0.1%w/v. The increase in particle size was possibly because of the presence of intermolecular hydrogen bonding (due to -OH groups) and intermolecular electrostatic repulsion (due to -NH₃⁺ groups) existing at the contour of CS (Qun and Ajun, 2006). When the concentration of CS increases, more molecules of CS tend to entrap NAR and crosslink with counter ion (TPP) to form a single larger particle (Fan *et al.*, 2012). This fact was revealed in the data obtained in the research and presented on table II.

ζ -potential was an index used to measure the stability of the nanoparticles. In most cases the higher the value of ζ -potential the larger the amount of charge on their surface, which leads to strong repulsive interaction among the nanoparticles, as the result the stability of the nanoparticles becomes higher (Lee, 2007). In the current study, positive ζ -potential was indicated by NARNPs use of 0.06%; 0.08%; and 0.10% CS and the zeta value ranges from +29.78 to +35.72mV. The ζ -potential of the NARNPs was summarized in table II. The data also demonstrates that the zeta potential of CS nanoparticles was significantly increased by increasing the CS concentration.

Morphology of NARNPs

Morphology of different NARNPs was investigated by using TEM. The morphology of NARNPs was found to be influenced by the concentration of chitosan. Chitosan with a concentration of 0.10% produce the biggest mean particles compared to chitosan with concentration of 0.06% and 0.08% as depicted by Figures 1(a) to 1(f) respectively. Results (Figure 1) generally showed that the shape of the nanoparticles was fairly spherical. The spherical shape make NARNPs more easy to be taken up by the cells than rod shape.

When compared with the results of measurements using the particle size analyzer (PSA), a visible difference in size was obtained

Table I. % EE of NARNPs at various concentrations of CS (Mean \pm SD, $n = 3$)

No	CS concentration (%)	EE (%)
1.	0.06	42.22 \pm 0.696
2.	0.08	64.45 \pm 0.028
3.	0.10	59.07 \pm 0.543

Table II. Dynamic Light Scattering and Zeta Potential Analysis of NARNPs

No.	Cs concentration (%)	Size (nm) X \pm SD	Zeta Potential (mV)
1.	0.06%	469.6 \pm 135.2	29.78 \pm 0.89
2.	0.08%	750.8 \pm 207.4	35.72 \pm 0.64
3.	0.10%	564.0 \pm 158.2	32.77 \pm 0.64




Figure 1. TEM images of NARNPs (a) chitosan of 0.06%-10.000x magnification; (b) chitosan of 0.08%-10.000x magnification; (c) chitosan of 0.10%-10.000x magnification; (d) chitosan of 0.06%-15.000x magnification; (e) chitosan of 0.08%-15.000x magnification; (f) chitosan of 0.10%-15.000x magnification.

by using TEM. This was caused by the diameter obtained from measurements using PSA shows the hydrodynamic diameter of the liquid medium, while the TEM measurements shows the diameter of the nanoparticles in dry conditions (Peng *et al.*, 2005)

FT-IR Analysis

NARNPs were prepared between chitosan and tripolyphosphate (TPP) by ionic gelation method. FTIR spectra of NARNPs were taken with potassium bromide pellets. FTIR studies of CS, NAR, Sodium TPP and NARNPs were performed to characterize the

chemical structure of nanoparticles. FTIR spectra of CS, NAR, Sodium TPP and NARNPs were shown in figure 2. The strong and wide peak in the 3500-3300 area was attributed to hydrogen-bonded O-H stretching vibration in the CS spectra. The peaks of N-H that stretches from primary amine and type II amide were overlapped in the same region. The peak for asymmetric stretch of C-O-C was found approximately at 1249 cm^{-1} . In CS-TPP nanoparticles the tip of the peak of 3400 cm^{-1} has a shift to 3435 cm^{-1} and gets wider with increased relative intensity indicating an enhancement of hydrogen bonding.




Figure 2. FT-IR of (a) CS, (b) NAR, (c) TPP, (d) NARNPS

In nanoparticles the peaks for N-H bending vibration of amine I at 1650cm^{-1} shifted and split to 1640cm^{-1} and 1603cm^{-1} . The crosslinked CS also indicates a P=O peak at 1157cm^{-1} . The results were associated to the linkage between phosphoric and ammonium ion, it was indicated that the triphosphoric groups of TPP were linked with ammonium groups of CS.

Differential Scanning Calorimetry (DSC) Analysis

Thermal analysis indicated that the DSC scan of the drug presented a sharp endothermic peak corresponding to its melting transition temperature. The DSC spectrum of the NAR showed a sharp endothermic peak with heating enthalpy 261.1716 J/g . Figure 3a, 3b, 3c and 3d illustrates DSC thermogram of NAR, CS, TPP, and NARNPs respectively. DSC spectrum of NARNPs does not exhibit the distinct peak of NAR from that conclusion it was described that in the NARNPs drug was in partial crystalline condition and there was no interaction between drug and polymer.

Cellular Uptakes Determination

In purpose to see the ability of the nanoparticles in entering the cells, then Cellular uptake was examined. The complex coaservation method used to bind the positive charge of CS and the negative charge of Na-TPP allow the nanoparticles to bind with the negative charged plasma membrane, continued with endocytosis process, and at last the nanoparticles enter the cells.

Cellular uptake was examined using Fluorescent microscopy (Figure 4). Colors ranging from green to yellow will be produced by NAR because of the chromophore group in this molecule. This result proves that the formulated NAR penetrates well into the cells. When being observed, the cells become fluorescent. The observation using fluorescent microscopy demonstrates that the NAR nanoparticles at CS concentration of 0.06%, 0.08%, and 0.1% provide a higher intensity of the green to yellow fluorescent when it was compared to the free NAR.




Figure 3. DSC thermogram of (a) NAR, (b) CS, (c) TPP, and (d) NARNPs.




Figure 4. Cellular uptake studies of NARNPs using fluorescence microscope. (A) control cell; (B) Free Naringenin; (C) NARNPs with chitosan of 0.06%; (D) NARNPs with chitosan of 0.08%; (E) NARNPs with chitosan of 0.10%-100x magnification. Qualitatively assayed by visual assessment. NAR will give a green to yellow fluorescent due to the chromophore group in this molecule.




Figure 5. Viability of T47D cells in cell culture with (A) Control cell; (B) Free Naringenin; (C) Blank Nanoparticles of chitosan 0.06%; (D) NARNPs with chitosan of 0.06%; (E) Blank Nanoparticles of Chitosan 0.08%; (F) NARNPs with chitosan of 0.08%; (G) Blank Nanoparticles of Chitosan 0.10%; (H) NARNPs with chitosan of 0.10% and incubation time (overnight) OVN. Viability of untreated cells was considered 100%. Each point represents the mean \pm SD of three determinations.

MTT Assay

To determine the level of NARNPs cytotoxicity against T47D cell line as the model of breast cancer cells, cytotoxic test was conducted. This test method was based on the conversion of yellow tetrazolium salt by succinate hydrogenase in mitochondria into formazan crystals (Mossmann, 1983). The

purple color obtained from formazan form was proportional to the number of living cells that was able to be measured through ELISA reader.

NAR which has anticancer activities with IC_{50} value of $509\mu M$ gives the toxic effect on the cancer cells line. The results (Figure 5) demonstrate that NARNPs with CS of 0.08%




Figure 6. Apoptosis assay against T47D cells line; (A) Free naringenin; (B) NARNPs with chitosan of 0.06%; (C) NARNPs with chitosan of 0.08%; (D) NARNPs with chitosan of 0.10%; (E) Control cell. DNA was stained using acridine orange-ethidium bromide and the pictures were taken under fluorescent microscope-100x magnification. Apoptosis cells (pointed by the arrow) gave an orange fluorescent.

has higher toxicity effect on T47D cell line compared to the free NAR after 24h incubation. Nanoparticle formulation increases the uptake of NAR into the cell as well as increases the effect of anti-cancer.

NARNPs with CS of 0.08% also have the highest EE and zeta potential among other NARNPs formula, hence its cytotoxicity effect was better than NARNPs with CS of 0.06% and 0.10%. Higher zeta potential make NARNPs easier to enter the cells, therefore more NAR can be delivered inside the cells to induce cytotoxicity.

Apoptosis Assay

Treatment of free NAR and NARNPs with CS concentration of 0.06%; 0.08%; and 0.10% were capable of stimulating apoptosis in T47D cells with an almost similar orange fluorescence intensity (Figure 6). The ability of inducing apoptosis was analyzed qualitatively by evaluating orange color in the cells. Based on the observation of its morphology, both free NAR and NARNPs show nucleus cells fragmentation. Increasing signs of apoptosis was higher in free NAR when it compared to cells treated by NARNPs. It was because of

crosslink between the CS and Na-TPP which causes increasing viscosity of polymer, so that the release mechanism through diffusion to the polymer was slower. This system was considered appropriate to control drug release. Observations need to be performed not only in overnight incubation. Nanoparticles with sustained release system was more suitable as a carrier of therapeutic agents for the treatment of cancer because of the risk of resistancy and adverse side effects on healthy cells. In addition, the presence of surface charge causes accumulation into cells through endocytosis and more specific distribution of cytotoxic active ingredients, thus reducing side effects. The size of a nanoparticle drug delivery system also causes the distribution towards smaller cells more easily and can be avoided by the reticulo endothelial clearance.

CONCLUSION

Chitosan nanoparticles-TPP conjugates have the capability to encapsulate naringenin hence increase the cellular uptake and cytotoxicity of naringenin against T47D cells line. NARNPs also can induce the apoptosis effect.

ACKNOWLEDGEMENT

Researchers gratefully thank to DIKTI (Directorate of Higher Education) Ministry of Education, Indonesia through “Hibah Bersaing” for financial support in this research.

REFERENCES

- Anbarassan B., Vennya VM., Niranjana VA., and Ramaprabhu S., 2013. Optimization of The Formulation and In-vitro Evaluation of Chloroquine Loaded Chitosan Nanoparticles Using Ionic Gelation Method. *J.Chem.Pharm.Sci.*6(1): 66-72
- Calvo P., Remuñán-López C., Vila-Jato JL., and Alonso MJ., 1997. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. *Journal of Applied Polymer Science.*63(1):125–132.
- Chang H., Mi M., Ling W., Zhu J., Zhang Q., Wei N., Zhou Y., Tang Y., and Yuan J., 2008. Structurally Related Cytotoxic Effects of Flavonoids on Human Cancer Cells in Vitro. *Arch. Pharm. Res.* 31(9):1137-1144.
- De Leo F., De Bosco SF., 2005. Citrus Flavonoids as Bioactive Compounds: Role, Bioavailability, Socio-economic Impact and Biotechnological Approach For Their Modification. *9th ICABR International Conference on Agricultural Biotechnology: Ten Years Later.* Rovello. Italy
- Dembinski A., Warzecha Z., Konturek SJ., Ceranowicz P., Dembinski M., Pawlik WW., Kusnierz-Cabala B., and Naskalski JW., 2004. Extract of grapefruit-seed reduces acute pancreatitis induced by ischemia/reperfusion in rats: possible implication of tissue antioxidants. *J. Physiol. Pharmacol.* 55:811
- Erlund I., Meririnne E., Alftan G., and Aro A., 2001. Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. *J. Nutr.* 131:235
- Fan W., Yan W., Xu Z., and Ni H., 2012. Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique. *Colloids and Surfaces B.* 90:21–27.
- Fitriasari A., Susidarti RA., and Meiyanto E., 2010. Peningkatan Efek Sitotoksik Doxorubicin oleh Naringenin Melalui Pemecuan Apoptosis Sel kanker Payudara MCF-7. *Jurnal Bahan Alam Indonesia.* 7 : 3
- Gopalakrishnan A., Xu CJ., Nair SS., Chen C., Hebbar V., and Kong AN., 2006. Modulation of activator protein-1 (AP-1) and MAPK pathway by flavonoids in human prostate cancer PC3 cells. *Arch. Pharmacol. Res.* 29: 633-644
- Hu B., Ting Y., Yang X., Tang W., Zeng X., and Huang Q., 2012. Nanochemoprevention by Encapsulation of (-)-epigallocatechin-3-gallate with Bioactive Peptides/Chitosan Nanoparticles for Enhancement of its Bioavailability. *Int. J. Mol. Sci.*13: 14251-14261
- Junedi S., Susidarti RA., and Meiyanto E., 2010. Peningkatan Efek Sitotoksik Doxorubicin oleh Naringenin pada Sel Kanker Payudara T47D Melalui Induksi Apoptosis. *Tesis.* Fakultas Farmasi Universitas Gadjah Mada.
- Kanno S., Tomizawa A., Hiura A., Osanai A., Shouji A., Ujibe A., Ohtake AT., Kimura K., and Ishikawa M., 2005. Inhibitory Effect of Naringenin on Tumor Growth in Human Cancer Cell Line and Sarcoma S-180-Implanted Mice. *Biol. Pharm. Bull.* 28(3): 527-530
- Kanno S., Tomizawa A., Ohtake T., Koiwai K., Ujibe M., and Ishikawa M., 2006. Naringenin induce apoptosis via activation of NF- κ B and necrosis involving in the loss of ATP in Human Promyeloleukimia HL-60 cells. *Toxicol.Lett.* 166: 131-139
- Le Gall G., DuPont MS., Mellon FA., Davis AL., Collins GJ., Verhoeyen ME., and Colquhoun IJ., 2003. Characterization and content of flavonoid glycosides in genetically modified tomato (*Lycopersicon esculentum*) fruits. *J. Agric. Food. Chem.*51:2438
- Lee YK., 2007. Chitosan and Its Derivatives for Gene Delivery, *Macromolecular Res.*15(3):195-201

- LeHoux JG., and Grondin F., 1993. Some Effects of Chitosan on Liver Function in The Rat. *Endocrinology*.132: 1078-1084
- Martien R., Loretz B., 2007.Chitosan Thioglycolic Acid Conjugate: An Alternative Carrier for Oral Nonviral Gene Delivery? *J. Biomed. Mater Res.* A.82(1):1-9
- Mokarram RA., Alonso MJ., 2006. Preparation and Evaluation of Chitosan Nanoparticles Containing Diphteria Toxoid as New Carriers for Nasal Vaccine Delivery In Mice. *Archives of Razi Institute*.61(1): 13-25
- Mosqueira V., Legrand P., Gulik A., Bourdon O., Gref R., Labarre D., and Barratt G., 2001. Relationship Between Complement Activation, Cellular Uptake and Surface Physicochemical Aspects of Novel PEG-modified Nanocapsules. *Biomaterials*. 22:2967-79
- Mossmann T., 1983. Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays. *J. Immunol. Meth.* 65:55–63.
- Peng J., Xing X., Wang K., Tan W., He X., and Huang S., 2005. Influence of Anions on The Formation and Properties of Chitosan-DNA Nanoparticles. *J. Nanosci. Nanotechnol*.5:713-7
- Qun G., Ajun W., 2006. Effects of molecular weight, degree of acetylation and ionic strength on surface tension of chitosan in dilute solution. *Carbohydrate Polymers*.64(1): 29–36.
- Rowe RC., Sheskey PJ., Owen SC., 2006. Chitosan. *HandBook of Pharmaceutical Excipients*, Pharmaceutical Press and American Pharmacist Association
- Stark T., Bareuther S., and Hofmann T., 2005. Sensory-guided decomposition of roasted cocoa nibs (Theobroma cacao) and structure determination of taste-active polyphenols. *J. Agric.Food. Chem.* 53:5407
- Thagele R., Mishra A., and Pathak AK., 2011. Formulation and Characterization of Clarithromycin Based Nanoparticulate Drug Delivery System.*Int.J.of Pharm.& Life Sci.(IJPLS)*. 2(1):510-115.
- Tripoli E., Guardia ML., Giammanco S., Majo DD., and Giammanco M., 2007. Citrus flavonoids: Molecular structure, biological activity and nutritional properties: A review. *Food Chem*.104:466–479.
- Wang H., Nair MG., Strasburg GM., Booren AM., and Gray JI., 1999. Antioxidant polyphenols from tart cherries (*Prunus cerasus*).*J. Agric. Food. Chem.* 47:840
- Winarti L., Martien R., and Sismindari, 2011. Formulation of Nanoparticle from short chain chitosan as gene delivery system and transfection against T47D cell line. *Indonesian.J.Pharm.* 3(11):204-211
- Xu Y., Hanna MA., 2007. Electrospayed Bovine Serum Albumin-loaded Tripolyphosphate Cross-linked Chitosan Capsule, Synthesis and Characterization. *J.Microencapsul.* 24: 143-151
- Zhang FY., Du GJ., Zhang L., Zhang CL., Lu WL., and Liang W., 2009. Naringenin Enhances the Anti-Tumor Effect of Doxorubicin Through Selectively Inhibiting the Activity of Multidrug Resistance-Associated Proteins but not P-glycoprotein. *Pharm. Res.* 26(4):914–924.

SUBSCRIPTION FORM

MAJALAH FARMASI INDONESIA (INDONESIAN JOURNAL OF PHARMACY)

I would like to subscribe Majalah Farmasi Indonesia (Indonesian Journal of Pharmacy) and have enclosed the information below.

Subscriber Details

Name :
Institution :
Address :
No. Telp./Mobile :
Email :

(Name and signature)

Subscription Details

Regular Subscription
From year to

or

Per Issue
Volume of Journal :
Issue of Journal :

Total amount of payment : Rp. / US.

Subscription Information

Indonesia (Local) rates:

Rp 60.000,00 per issue
Rp 240.000,00 per year for individual
Rp 240.000,00 per year for institution
All rates excludes 30% shipping charge

International Rates

USD 10.00 per issue
USD 35.00 per year
All rates excludes 30% shipping charge

Payment in the form of cheques, international money orders or bank draft should be made in favour of journal editor and sent directly to:

Dr. Agustinus Yuswanto

Editor-in-Chief,

Majalah Farmasi Indonesia (Indonesian Journal of Pharmacy)

Faculty of Pharmacy, Universitas Gadjah Mada, Sekip Utara, Yogyakarta Indonesia, 55281.

Telp: 62-274-6645911, 62-274-6492566 Fax : 62-274-543120

No. VA : 8888803014100003. Mandiri, an. UGM.FA. KAF Penerimaan Langganan Jurnal

INSTRUCTIONS FOR AUTHORS

Indonesian Journal of Pharmacy (Formerly Majalah Farmasi Indonesia ISSN : 0126-1037) abbreviated Indonesian J. Pharm., firstly published in 1972, is a quarterly published, open access, peer-reviewed, and online international pharmacy journal. Indonesian J. Pharm. aims to serve the updated scientific knowledge for international researchers in pharmaceutical fields.

Indonesian Journal of Pharmacy is indexed in Google Scholar, SCIRUS, Genamics Journal Seek New Jersey USA, Indonesian Scientific Journal Database (ISJD), EBSCO Publishing Database, Index Copernicus. Inherent Digital Library UGM, CABI, DOAJ, Crossref, Pro-Quest, Indonesian Journal of Pharmacy is under planning to indexed with Scopus, Open J. Gate and Biological abstract

Indonesian J. Pharm. is a periodic scientific publication, which is published four times a year. Indonesian J. Pharm uses a peer-review system in the selection of papers. Indonesian J. Pharm receives the publication article about research results, surveys, and literature reviews which is closely related to the field of pharmacy and health. The article published is the result of selection that has been approved by Editors Board. It also has never appeared in another publication.

Indonesian J. Pharm accepts review articles, original research articles and short communications in English. The journal includes various fields of pharmaceuticals sciences such as Pharmacology and Toxicology, Pharmacokinetics, Community and Clinical Pharmacy, Pharmaceutical Chemistry, Pharmaceutical Biology, Pharmaceutics, Pharmaceutical Technology, Biopharmaceutics, Pharmaceutical Microbiology and Biotechnology, Regulatory Affairs and Pharmaceutical Marketing Research, and Alternative medicines.

The article is written in English with Arial font number 12 and compiled systematically.

- Original research articles – original research papers which have not been published previously and should not exceed 3000 words (including allowance for no more than 6 tables and figures or other illustrations).
- Review articles – will be taken into account for publication in the field of the journal's scope. The review should not exceed 5000 words (including allowance for no more than 6 tables and figures or other illustrations).
- Short communications – Short communications of up to 1500 words, describing work that may be of a preliminary nature but which merits immediate publication.

MANUSCRIPT STYLE

The manuscripts should be divided into the following sections:

- (a) An abstract (maximal 200 words) embodying the main conclusion and giving the essential information.

- (b) Introduction – should give the research objective and a brief statement of previous relevant work with references;
- (c) Material and Methods
- (d) Results and Discussion
- (e) Conclusion
- (f) Acknowledgement
- (g) References.

The article is written in English with Arial font number 12, double space, maximal 10 pages and with margin 4, 4, 3 and 3 from top, left, bottom and right, respectively. In general, the contents should comprise of Abstract accompanied with 3 -5 key words, Introduction, Materials and Methods, Results and Discussion, Conclusion, Acknowledgement and References.

All illustrations including figures, charts and graphs, must be labeled (in the bottom), numbered (1, 2, 3 etc) and supplied on separate pages from the text. The desired placement in the text should be clearly indicated. These illustrations should be referred to and numbered serial, as figures. All illustrations should be clearly drawn in permanent ink or photographed in sharp black and white and reproduced in the form of high – contrast glossy prints or digital images and provided in camera ready form.

References in the text should be denoted by giving the name(s) of the author(s). All alphabetically ordered references list should be included at the end of the manuscript. All references cited in the text must appear in the reference list. Authors are responsible for the accuracy and completeness of all information in the reference.

The journal names in the References section need to be abbreviated as per the journal guidelines. Use the following link to search for journal abbreviations:
<http://scieng.library.ubc.ca/coden/>

For example,

Journal article

Kachrimanis K., Rontogianni M. Malamataris S., 2010. Simultaneous quantitative analysis of mebendazole polymorphs A-C in powder mixtures by DRIFTS spectroscopy and ANN modeling. *J. Pharm. Biomed. Anal.* 51: 512-520.

Wipf P., Aslan DC., Southwick EC., Lazo JS., 2001, Sulfonylated aminothiazoles as new small molecule inhibitors of protein phosphatases. *Bioorg. Med. Chem. Lett.*, 11, 313-317

Article in Press:

Lukitaningsih E., Saadah M., Purwanto, Rohman A., 2012. Quantitative analysis of lard in lotion cosmetics formulation using FTIR spectroscopy and partial least square calibration. *J. Am. Oil Chem. Soc.* DOI. 10.1007/s11746-012-2052-8.

Book chapters:

Che Man YB., Syahariza ZA., Rohman A., 2010. Chapter 1. Fourier transform infrared (FTIR) spectroscopy: development, techniques, and application in the analyses of fats and oils, in *Fourier Transform Infrared Spectroscopy*, edited by Oliver J. Ress, Nova Science Publishers, New York, USA. pp 1 – 26.

Books:

Miller JN., Miller JC. 2005. *Statistics and Chemometrics for Analytical Chemistry*. 5th ed. Pearson Education Limited, Edinburgh Gate Harlow, England. pp. 213 – 239.

Thesis:

Ritmaleni L., 2004, Application of spiro-epoxide in synthesising biologically important targets, *Thesis*, University of Bristol, UK

Internet:

Wilson D., 20 November 1995. Summary of Citing Internet Sites. *NETTRAIN Discussion List*, (Online), (NETTRAIN@ubvm.cc.buffalo.edu, accessed 22 November 1995).

Manuscripts and other communication must be directed to the editorial office of the Journal at the following address:

Dr. Agustinus Yuswanto
Editor-in-Chief,
Indonesian Journal of Pharmacy
Faculty of Pharmacy, Universitas Gadjah Mada, Sekip Utara, Yogyakarta Indonesia,
55281.

Submission can be sent directly to Email: mfi@ugm.ac.id/

or

Online submission via <http://indonesianjpharm.farmasi.ugm.ac.id>

PUBLICATION CHARGES

A charge of (USD 100) for each manuscript that is accepted, **except for invited paper (free of charge)**. Cost of color reproduction will be charged to the authors (USD 50 per page*) except invited paper. Indonesian J. Pharm, offers the author for Indonesian-English translation, and charge per page is Rp. 75.000,00.